Department of Gastroenterology, Ankara Education and Research Hospital, Ankara, Turkey.
Helicobacter. 2011 Feb;16(1):52-4. doi: 10.1111/j.1523-5378.2010.00817.x.
To document the efficacy and tolerability of 14-day moxifloxacine-tetracycline-lansoprazole (MTL) regimens for Helicobacter pylori (Hp) eradication as a first-line therapy.
Fifty-six Hp-positive patients were enrolled. Patients were considered eligible for the study if they underwent upper gastrointestinal endoscopy, and Hp infection was diagnosed through histologic examination of antral and body bioptic samples. Primary end point of this study was to evaluate the eradication rate of 14-day MTL regimen therapies. Hp eradication was assessed using the 13C urea breath test performed. All patients were asked to fill in a validated questionnaire to report therapy-related side effects. Each symptom was graded from absent or present.
Fifty-six patients (29 men and 27 women) were enrolled. The studied therapeutic regimens were completed by 96.4% patients. Two dropouts occurred in the MTL group because of side effects. The eradication rate in MTL regimens was 55.4%. The overall prevalence of side effects was high in the MTL group.
The MTL regimen failed to achieve the recommended eradication rates and had higher adverse effect rate. Hence, MTL regimen does not seem to be a suitable choice as a first-line Hp eradication therapy.
记录 14 天莫西沙星-四环素-兰索拉唑（MTL）方案治疗幽门螺杆菌（Hp）的疗效和耐受性，作为一线治疗。
纳入 56 例 Hp 阳性患者。如果患者接受上消化道内镜检查，并且通过胃窦和体活检样本的组织学检查诊断为 Hp 感染，则认为符合本研究条件。本研究的主要终点是评估 14 天 MTL 方案治疗的根除率。使用 13C 尿素呼气试验评估 Hp 根除情况。所有患者均被要求填写一份经过验证的问卷，以报告与治疗相关的副作用。每个症状均按有无进行分级。
共纳入 56 例患者（29 名男性和 27 名女性）。96.4%的患者完成了研究治疗方案。MTL 组有 2 例因副作用而脱落。MTL 方案的根除率为 55.4%。MTL 组的总体不良反应发生率较高。
MTL 方案未能达到推荐的根除率，且不良反应发生率较高。因此，MTL 方案似乎不是 Hp 根除治疗的首选方案。
